32 A FLASH of Hope - Preventing Recurrent Glioblastoma

Clicks: 22
ID: 326747
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #98 of 286 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 286 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction Glioblastoma (GBM) remains the most aggressive and lethal primary brain tumour, with a 5-year survival rate of only ∼13% and a recurrence rate approaching 90% within two years of diagnosis. Current treatment options include surgery followed by radiotherapy and chemotherapy, but these are limited by radioresistance and the inability to eliminate residual infiltrative cells. There is an urgent need for more effective, kinder treatment strategies that prevent recurrence. This project has, so far, explored two promising therapeutic avenues: ultra-high dose-rate FLASH radiotherapy and metabolic inhibition, with the long term goal of combining both modalities to target recurrent GBM. Methods Patient-derived GBM primary and recurrent spheroid models of the infiltrative margin (GIN98R, GIN38, GIN44) were exposed to either conventional dose-rate radiotherapy or FLASH dose-rate radiotherapy at doses between 0-20Gy. Changes in spheroid area were quantified to assess tumour control. Separately, the metabolic inhibitor 3-bromopyruvate (3-BP) was applied to GBM spheroids to evaluate its impact on tumour cell viability. Statistical analysis was performed to determine treatment efficacy across conditions. Results FLASH radiotherapy demonstrated enhanced control of GBM spheroid growth compared with conventional radiotherapy, particularly at doses ≥10Gy, and was notably effective against the GIN98R cell line, which has shown evidence of radioresistance. Independently, 3‑BP significantly reduced tumour viability in GIN38 and GIN44 spheroids. This metabolic inhibition exploits the altered energy pathways on which GBM cells rely, offering a therapeutic vulnerability. Conclusions Our findings indicate that residual GBM cells can be targeted through two distinct but complementary mechanisms: energy metabolism inhibition and ultra-high dose-rate FLASH irradiation. These results lay the groundwork for a future combined modality strategy, with the potential for a synergistic and less toxic therapeutic option to prevent GBM recurrence.
Reference Key
openalex_W7204463214 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Riddhi Sharma, William Timbury, Sean Gettings, Raymond Shek, Stuart Smith, Ruman Rahman, Nora Bourbia
Are you one of these authors? Claim your profile
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag172.074
URL
https://academic.oup.com/neuro-oncology/article-pdf/28/Supplement_1/noag172.074/70805971/noag172.074.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.